Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically driven, global, full-service clinical contract research organization (CRO) that regularly issues detailed financial and operational updates. This news page aggregates Medpace news, including quarterly and annual earnings releases, conference call announcements, and other disclosures that matter to investors following MEDP stock and the clinical research sector.
Medpace’s press releases focus on revenue trends, GAAP net income, EBITDA and EBITDA margin, backlog levels, and net new business awards, along with net book-to-bill ratios. The company also provides financial guidance ranges for upcoming periods, discussing expected revenue, net income, and EBITDA, as well as assumptions related to tax rates, interest income, and diluted share counts. These updates help readers understand how demand for Medpace’s Phase I–IV clinical development services is evolving over time.
In addition to earnings results, Medpace frequently announces the dates and times of upcoming earnings releases and conference calls, along with webcast access details and references to supplemental slide presentations in its investors section. The company’s news also touches on capital allocation decisions, such as stock repurchase program authorizations and remaining repurchase capacity, and occasionally on financing arrangements, as reflected in filings related to its unsecured credit facility.
Because Medpace operates as a global CRO serving biotechnology, pharmaceutical and medical device sponsors, its news flow offers insight into the broader outsourcing environment for clinical research and development. Investors, analysts, and industry observers can use this page to review historical announcements, monitor new earnings releases, and track changes in guidance, backlog, and booking trends over time.
Medpace (Nasdaq: MEDP) reported strong fourth-quarter and full-year 2025 results, driven by robust revenue growth and solid bookings.
Q4 revenue was $708.5M (+32.0% YoY) and GAAP net income was $135.1M ($4.67/diluted). Full-year 2025 revenue was $2,530.2M (+20.0% YoY) with GAAP net income of $451.1M ($15.28/diluted). The company repurchased 2,961,924 shares for $912.9M in 2025 and provided 2026 guidance of $2.755B–$2.855B revenue and GAAP net income of $487M–$511M.
Medpace (Nasdaq: MEDP) will report fourth quarter and fiscal year 2025 financial results after market close on Monday, February 9, 2026. The company will host a conference call to discuss results on Tuesday, February 10, 2026 at 9:00 a.m. ET.
Telephone participants must register in advance to receive a confirmation email with dial-in details and a unique PIN. A live webcast, supplemental slide presentation, and a replay (available ~one hour after the call ends) will be available in the Investors section at investor.medpace.com.
Medpace (Nasdaq: MEDP) reported third quarter 2025 revenue of $659.9M, up 23.7% YoY, with net new business awards of $789.6M (+47.9%) and a net book-to-bill of 1.20x. GAAP net income was $111.1M or $3.86 per diluted share; net income margin was 16.8% versus 18.1% a year ago. EBITDA rose 24.9% to $148.4M (22.5% margin). Cash and equivalents were $285.4M and operating cash flow in Q3 was $246.2M. Year-to-date share repurchases totaled 2,961,924 shares for $912.9M, with $821.7M remaining on the buyback. Full‑year 2025 guidance: revenue $2.48–2.53B, GAAP net income $431–439M, EBITDA $545–555M.
Medpace Holdings (NASDAQ:MEDP) has scheduled its third quarter 2025 financial results announcement for October 22, 2025 after market close. The company will host a conference call on Thursday, October 23, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will be available prior to the call.
Medpace Holdings (NASDAQ:MEDP) reported strong Q2 2025 financial results with revenue increasing 14.2% to $603.3 million compared to the prior year. The company achieved a net book-to-bill ratio of 1.03x with net new business awards of $620.5 million, up 12.6% year-over-year.
GAAP net income reached $90.3 million ($3.10 per diluted share), while EBITDA grew 16.2% to $130.5 million with a 21.6% margin. The company's backlog slightly decreased by 1.8% to $2.87 billion. During Q2, Medpace repurchased 1.75 million shares for $518.5 million.
For full-year 2025, Medpace forecasts revenue between $2.42-2.52 billion, representing 14.7-19.5% growth, with GAAP net income expected between $405-428 million.
Medpace Holdings (Nasdaq: MEDP) has scheduled its second quarter 2025 financial results announcement for Monday, July 21, 2025, after market close. The company will host a conference call on Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will be available prior to the call.
Medpace Holdings (MEDP) reported Q1 2025 financial results with revenue reaching $558.6 million, a 9.3% increase from $511.0 million in the prior year. GAAP net income rose to $114.6 million ($3.67 per diluted share), up from $102.6 million ($3.20 per diluted share) year-over-year.
The company's backlog decreased 2.1% to $2.85 billion, with net new business awards of $500.0 million resulting in a book-to-bill ratio of 0.90x. EBITDA grew 2.6% to $118.6 million with a 21.2% margin.
During Q1, Medpace repurchased 1.19 million shares for $389.8 million and received board approval for an additional $1.0 billion share repurchase program. The company projects 2025 revenue between $2.14-2.24 billion, representing 1.5-6.2% growth, with GAAP net income forecast at $378.0-402.0 million.
Medpace Holdings (Nasdaq: MEDP) has announced it will release its first quarter 2025 financial results after market close on Monday, April 21, 2025. The company will hold a conference call to discuss these results on Tuesday, April 22, 2025, at 9:00 a.m. ET.
Participants must pre-register through a provided link to join the conference call. A unique PIN and dial-in number will be provided upon registration. It is recommended to join 10 minutes before the event start. The webcast will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available prior to the call.
Medpace Holdings (MEDP) reported Q4 2024 financial results with revenue increasing 7.7% to $536.6 million. Net new business awards were $529.7 million, representing a net book-to-bill ratio of 0.99x. GAAP net income rose significantly to $117.0 million ($3.67 per diluted share), with a net income margin of 21.8%.
For full-year 2024, revenue grew 11.8% to $2,109.1 million, with net new business awards of $2,230.0 million and a book-to-bill ratio of 1.06x. The company's backlog increased 3.2% to $2,902.2 million. EBITDA increased 32.5% to $480.2 million.
Looking ahead, Medpace provided 2025 guidance projecting revenue between $2.110-2.210 billion and GAAP net income of $378.0-402.0 million. The company also announced a $600 million increase to its stock repurchase program.
Medpace Holdings (MEDP) has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on Monday, February 10, 2025. The company will host a conference call on Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast of the call will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available on the website before the call begins.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
